Meetings and publications | |
>> VHPB meetings |
Viral Hepatitis Prevention Board
Antwerp, Belgium, March 12-13, 2009
HEPATITIS A AND E:
UPDATE ON
PREVENTION AND EPIDEMIOLOGY
Thursday, March 12, 2009
Session 1: Opening and
objectives
Chair: Paolo Bonanni, Steven
Wiersma
Hepatitis A
Session 2: Has the time come to control
hepatitis A globally?
Chair: Paolo Bonanni, Steven
Wiersma
08.50 09.20
Summary of major findings and conclusions of Global Hepatitis A
meeting, Miami dec. 2007. 563Kb (.pdf)
Pierre Van
Damme (UA Antwerpen, Belgium)
09.20 09.40
What are the risk factors with an impact on fatality rate in
fulminant hepatitis A? 537Kb (.pdf)
Daniel Shouval
(Hadassah-Hebrew University Hospital, Jerusalem, Israel)
09.40 09.25 Discussion
09.55 10.10 Coffee break
Session 3: Update on Hepatitis A epidemiology,
prevention and control
Chair: Daniel Shouval, Vana
Papaevangelou
3a. Epidemiology
10.10 10.25
Increase in Hepatitis A cases in the Czech Republic in
2008. 270Kb (.pdf)
J Cαstkovα,(National
Institute of Public Health, Prague, Czech Republic)
10.25 10.40
Community-wide outbreak of Hepatitis A in Latvia.
2.8Mb (.pdf)
J Perevoscikovs (Public Health Agency,
Riga, Latvia)
10.40 10.50 Discussion
3b. Prevention
10.50 11.05
Long-term immunity induced by hepatitis A vaccines: an
update. 264Kb (.pdf)
Koen Van Herck (UA
Antwerpen, Belgium)
11.05 11.20
Correlation between humoral and cellular immune responses and the
expression of the hepatitis A receptor HAVcr-1 on T cells after Hepatitis A
vaccination in high and low responder. 772Kb (.pdf)
Ursula
Wiedermann (Medical University, Vienna, Austria)
11.20 11.30 Discussion
3c. Control
11.30 11.45
EVENT, a network for harmonization typing of HAV and for alerting
on hepatitis A outbreaks 111Kb (.pdf)
Helene Norder
(SMI , Stockholm, Sweden)
11.45 12.05
Global overview on the effectiveness of Hepatitis A vaccination
programs Hepatitis A vaccination in high and low responder. 623Kb
(.pdf)
Umid Sharapov (CDC, Atlanta, USA)
12.05 13.05 Lunch
Chair:Rui Marinho, John Ward
13.05 13.25
Update on Hepatitis A epidemiology and prevention in
WHO European Region. 132Kb (.pdf)
David Mercer
(WHO Euro region)
13.25 13.45
Review of the Hepatitis A WHO position paper: need for an
update? 196Kb (.pdf)
Steven Wiersma (WHO)
13.45 14.00 Discussion on Hepatitis A lessons learned and future initiatives
Hepatitis E
Session 4: Introduction on Hepatitis
E
Chair: Alessandro Zanetti, Selim Badur
14.10 14.40
Hepatitis E from A to Z: Discovery and
Characterization. 2.9Mb (.pdf)
Robert Purcell
(National Institutes of Health, Maryland,USA)
14.40 14.55 Coffee break
Session 5: Virology, pathogenesis and natural
history
Chair: Alessandro Zanetti, Selim Badur
14.55 15.15
Molecular epidemiology of hepatitis E, taxonomy, molecular
biology,genotypes and subtypes. 299Kb(.pdf)
Helene
Norder (SMI , Stockholm, Sweden)
15.15 15.35
Pathogenesis and natural history of hepatitis E. 1.1Mb
(.pdf)
Krzysztof Krawczynski (CDC,
Atlanta, USA)
15.35 15.50 Discussion
Session 6: Zoφnotic transmission of
HEV
Chair: Pierre Van Damme, Francoise
Roudot-Thoraval
15.50 16.10
Hepatitis E: a curious zoφnosis. 753Kb
(.pdf)
Nicole Pavio (AFSSA LERPA-ENVA-INRA, Ecole
Nationale Veterinaire dalfort, France )
16.10 16.30
Distribution of hepatitis E virus in the environment. 999Kb
(.pdf)
Rosina Girones (University of Barcelona,
Spain)
16.30 16.45
Endemic HEV in Europe.
16.45 17.00 Discussion
17.00 End meeting day 1
18.30 Drink at the Town hall
20.00 Dinner
Friday, March 13, 2009
Session 5 (continu): Virology, pathogenesis
and natural history
Chair: Daniel Lavanchy, Hal
Margolis
09.00 09.20
Hepatitis E virus and chronic hepatitis in organ-transplant
recipients. 1.4Mb (.pdf)
Nassim Kamar (Centre
Hospitalier Universitaire, Rangueil, France)
Session 7: Hepatitis E and its emergence in
(non-)endemic areas
Chair: Daniel Lavanchy, Hal
Margolis
09.20 09.35 UK
Autochthonous hepatitis E in Southwest England. 461Kb
(.pdf)
Harry R Dalton (Royal Cornwall Hospital
Trust, UK)
09.35 09.50 The Netherlands
Non-travel related Hepatitis E virus infections in the
Netherlands. 472Kb (.pdf)
Erwin DuizerRIVM,
Bilthoven, The Netherlands)
09.50 10.05 France
Acute hepatitis E in south-west France over a 5-year
period. 655Kb (.pdf)
Jean Michel Mansuy (CHU
Toulouse, France)
10.05 10.20 Germany
Hepatitis E Virus Infection in Germany. 173Kb
(.pdf)
Wolfgang Jilg (University of Regensburg,
Germany)
10.20 10.35 Spain
Prevalence of hepatitis E virus infection in children in Northeast
of Spain. 138Kb (.pdf)
Maria Buti -
presented by Rosina Girones (University of Barcelona,
Spain)
10.35 10.50 Coffee break
Chair: Koen Van Herck, Mark Kane10.50 11.05 Italy
Hepatitis E in Italy. 361Kb (.pdf)
Alessandro
Zanetti (University of Milan, Italy)
11.05 11.20
The seroprevalence of HEV in the National Health and Nutrition
Sample of the United States population. 647Kb
(.pdf)
Kenrad Nelson> (John Hopkins School of
Medicine, Baltimore, Maryland,USA)
11.20 11.40
Hepatitis E in Asian Region. 3.9Mb (.pdf)
Emily
Gurley (Infectious Disease and Vaccine Sciences Program,
Dhaka,Bangladesh)
11.40 12.00 Discussion
Session 8: Vaccine against HEV and its
future
Chair: Koen Van Herck, Mark Kane
12.00 12.20
Safety and efficacy of a recombinant hepatitis E vaccine.
194Kb (.pdf)
Bruce Innis (GSK, Philadelphia,
USA)
12.20 12.40
Hepatitis E vaccine: Clinical experience. 717Kb
(.pdf)
Mrigendra Shrestha (institute Walter Reed/ AFRIMS
Research Unit Nepal, Nepal)
12.40 13.00
Randomized-controlled phase II clinical trial of a bacterially
expressed recombinant hepatitis E vaccine. 1Mb (.pdf)
JamesWai-kuo Shih (National Institute of Diagnostics and
Vaccine Development in Infectious Diseases, Xiamen , China)
13.00 13.15 Discussion
13.15 14.45 Lunch
Session 9: Conclusions of the
meeting
Chair: Johannes Hallauer, Wolfgang Jilg
14.00 15.00
Presentation of the VHPB meeting conclusions. 133Kb
(.pdf)
D. FitzSimons
15.00 Close of the meeting